

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment –Scoping

MTA Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation), and, if so, what are they?

1. During the development of TA201 consultees had expressed the view that not recommending omalizumab for children aged 6 to 11 years was unfair because omalizumab was recommended under specific circumstances for children aged 12 years and older in NICE technology appraisal 133. The fact that omalizumab for children aged 6 to 11 years was considered separately from omalizumab for people older than 12 years was a result of the timing of the regulatory process in the younger paediatric indication, which was outside NICE's control. In TA201, the Committee needed to make a decision based on the evidence before it and the ICER for omalizumab in children was very high. The Committee concluded that it would be preferable to develop a single piece of guidance giving recommendations for all age groups, and that the most appropriate way to proceed would be to review the recommendations for all age groups together at the earliest opportunity.

During the draft scope consultation the following potential issues were raised:

2. People from certain races are not accessing health care support as much as other racial groups.
3. People from rural locations may not have equal access to treatment

Technology appraisals: Scoping

Equality impact assessment for the proposed multiple technology appraisal of omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201)

Issue date: Sept 2011

4. Overweight people are not included in dosing table in the SPC

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

1. Addressed in this appraisal
2. Service configuration/ implementation issue, which cannot be addressed in a Technology Appraisal.
3. Service configuration/ implementation issue, which cannot be addressed in a Technology Appraisal.
4. Issue cannot be addressed by Appraisal Committee as it can only appraise a technology within the marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes necessary.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

None identified.

Approved by Associate Director (name): ...Elisabeth George.....

Date: 22 09 11